10-Q quarterly report · filed Nov 5, 2026

Disc Medicine, Inc. (IRON) Q3 2026 10-Q Quarterly Report

Short answer

Disc Medicine, Inc. (IRON) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026.

Q3 2026 key financials · XBRL

Net income
−$60M
+4.5% YoY · −0.0% QoQ
EPS (diluted)
−$1.53
+14.0% YoY · +0.6% QoQ

Source: XBRL data from the Disc Medicine, Inc. (IRON) Q3 2026 10-Q on SEC EDGAR. USD.

Disc Medicine, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, no product sales since inception
  • Net loss $59.5M vs $62.3M YoY, operating expenses $64.2M vs $67.7M
  • Best R&D performer: selcodebart expenses $8.4M, up $1.1M; lowest DISC-3405 at $4.9M, down $7.0M
  • Cash, equivalents and securities $682.8M; October offering added approximately $485.9M net
  • Operating cash outflow $146.6M through nine months; funding expected into 2030, APOLLO supports NDA resubmission by year-end 2026

Risk Factors

  • Newly triggered supply-chain risk: BIOSECURE Act restrictions and China tariffs may disrupt foreign vendors, materials, and clinical trials
  • Most material regulatory update: FDA’s February 2026 CRL rejected bitopertin accelerated approval, requiring APOLLO clinical-benefit evidence
  • Near-term development risk: APOLLO topline results remain subject to FDA review before planned NDA resubmission by end-2026
  • Financial risk: $200.0 million senior secured term loan matures December 1, 2029, with minimum qualified-cash covenant
  • Liquidity risk: Management expects cash, cash equivalents, and marketable securities to fund operations into 2030, based on uncertain assumptions

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Disc Medicine, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.